查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1995211

基因型鉴定市场：依检体类型、技术、应用和最终用户划分－2026-2032年全球市场预测

Genotyping Market by Sample Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，基因型鉴定市值将达到 1,543.8 亿美元，到 2026 年将成长至 1,657.6 亿美元，到 2032 年将达到 2,824.8 亿美元，复合年增长率为 9.01%。

主要市场统计数据
基准年 2025 1543.8亿美元
预计年份：2026年 1657.6亿美元
预测年份 2032 2824.8亿美元
复合年增长率 (%) 9.01%

简要概述基因型鉴定的进步、市场动态以及影响组织如何利用基因组数据产生可操作结果的策略挑战。

基因型鉴定如今已成为生命科学、农业和临床实践等各个领域的基础性能力，这得益于技术的成熟和不断扩大的应用需求。随着精准生物学从发现走向实用化，相关人员需要一个清晰的框架，来理解核心技术、最终用户需求和样本多样性如何相互作用，从而创造机会并带来挑战。本文将当前趋势置于这一更广泛的背景下进行概述，重点关注检测可重复性、样本来源、工作流程整合和法规遵从性等实际问题。

新的技术突破、监管驱动因素和经营模式转型正在重新定义基因型鉴定的实践和商业性部署。

基因型鉴定领域正经历一系列变革，这些变革正在重塑调查、诊断和应用育种计画的运作方式。在技​​术层面，定序化学的不断改进以及数位PCR和先进微阵列技术的整合，提高了灵敏度，缩短了周转时间，并增强了实验设计的灵活性。生物资讯流程的改进进一步放大了这些进步，减少了分析瓶颈，并提高了不同样本类型中变异检测的可靠性。

对 2025 年美国推出的关税措施对基因型鉴定生态系统的供应链、筹资策略和创新的影响进行全面评估。

美国2025年实施的关税措施对基因型鉴定生态系统产生了复杂的影响，波及供应链、零件采购和筹资策略。近期营运方面的影响包括进口设备和试剂的接收成本增加，促使一些采购商重新审视其供应商组合併探索替代筹资策略。因此，采购团队更重视供应商的韧性、本地库存缓衝以及合约保障措施，以降低关税导致的价格波动风险。

详细的细分洞察揭示了技术、应用、最终用户和样本类型的趋势，这些趋势影响着产品的采用和创新需求。

详细的细分框架阐明了基因型鉴定整体情况价值和技术差异的集中方向。在技​​术层面，微阵列、PCR 和定序平台之间的差异导致了截然不同的应用情境和投资模式。微阵列技术，包括比较基因组杂合反应和 SNP 晶片，在目标明确、注重成本效益的基因型鉴定中仍发挥重要作用，并被广泛应用于大规模变异筛检。 PCR 方法分为数位 PCR 和即时PCR两种形式，二者优势互补。数位 PCR 能够对低等位基因频率 (LAF) 进行超灵敏定量，而即时PCR则为常规检测提供了高通量且经济高效的工作流程。定序包括传统的 Sanger 定序和次世代定序，其中次世代定序可进一步细分为EXOME、标靶定序和全基因组定序，其差异在于基因组分析的范围和下游分析的复杂性。

美洲、欧洲、中东和非洲以及亚太地区的区域战略展望：重点关注竞争优势和能力差距

区域趋势对基因型鉴定领域的策略和营运有显着影响，每个区域都拥有其独特的优势、限制和商业管道。在美洲，强大的研究基础设施和紧密的临床及商业检查室网路正在推动技术的快速应用和蓬勃发展的供应商生态系统，而政策变化和采购惯例则可能加速或阻碍引进週期。同时，欧洲、中东和非洲地区的环境则呈现出异质性，有些地区拥有健全的法规结构，而有些地区则存在能力差异，这既为集中式诊断服务创造了机会，也为不同市场间的公平获取带来了挑战。该地区的相关人员经常强调合规性、资料保护和跨境合作是关键的策略考量。

竞争情报和企业定位分析，揭示领先基因型鉴定公司的策略重点、合作趋势和产能投资。

基因型鉴定领域的企业行为体现了技术主导差异化和策略组合管理的整合。主要企业正集中资源开发高价值能力，例如从样本到结果的整合工作流程、云端分析以及仪器和共同检验的试剂组合。仪器供应商和软体供应商之间的合作日益普遍，这不仅能够更紧密地整合检查室工作流程和分析，还能加快获得可操作结果的速度。同时，一些公司正在寻求垂直整合，以管理关键耗材并保护利润率免受供应链中断的影响。

为产业领导者提供具有重大影响力的策略建议，以加速技术采用、确保价值链并在基因型鉴定市场中获取价值。

产业领导者应优先采取一系列措施，以加强其策略定位和业务永续营运。首先，他们应透过在特定检体类型和对客户至关重要的应用场景下检验平台效能，使技术选择与最终用户的工作流程相符。这种配对可以减少下游返工，并加快部署速度。其次，他们应探索区域製造或经销伙伴，以实现供应商关係多元化，并降低关税风险和物流中断的影响。强调合约保障和库存策略有助于在控製成本的同时确保服务的连续性。

严谨的调查方法，详细说明了基因型鉴定研究过程中的资料来源、专家参与、检验过程和伦理保障措施。

本执行摘要依据的研究采用了一种多方面的方法，旨在确保研究的严谨性、透明度和可重复性。主要资料收集包括对临床检查室、农业育种计画和学术研究计画​​的从业人员进行结构化访谈，并辅以与采购和监管专家的咨询，以了解营运和政策方面的观点。次要研究则整合了同行评审的文献、监管指南、仪器和检测方法文檔以及公开的企业资讯披露，从而对研究结果进行多方面的检验，并将技术进步置于具体的背景之中。

整合相关人员的洞见：不断发展的基因型鉴定领域面临的策略挑战概述及实现韧性和成长的途径

总而言之，基因型鉴定技术正从局限于专业检查室的模式转变为支持大规模诊断、农业和研究的去中心化应用。定序、微阵列和PCR等技术的进步正在拓展可行检测的范围，而不断演变的经营模式和监管政策的调整则正在塑造其应用路径。 2025年的关税趋势凸显了供应链韧性的重要性，并加速了区域製造和供应商多元化的讨论。细分市场分析表明，技术选择必须根据应用需求、最终用户能力以及不同样本类型带来的独特挑战进行客製化。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章基因型鉴定市场样本（按类型划分）

  • 动物
  • 人类
  • 微生物
  • 植物

第九章基因型鉴定市场：依技术划分

  • 微阵列
    • 比较基因杂合反应
    • SNP晶片
  • PCR
    • 数位的
    • 即时的
  • 定序
    • 新一代
      • EXOME
      • 目标类型
      • 全基因组
    • 桑格

第十章：基因型鉴定市场：依应用领域划分

  • 农业
    • 作物改良
    • 畜牧养殖
  • 临床诊断
    • 癌症谱分析
    • 病原体检测
  • 研究
    • 基因表现分析
    • 基因突变研究

第十一章基因型鉴定市场：依最终用户划分

  • 学术研究机构
  • 诊断检测实验室
  • 製药和生物技术公司

第十二章基因型鉴定市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章基因型鉴定市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章基因型鉴定市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国基因型鉴定市场

第十六章：中国基因型鉴定市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Merck KGaA
  • Oxford Nanopore Technologies plc
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Revvity, Inc.
  • Standard BioTools Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-A77F2EE7AB77

The Genotyping Market was valued at USD 154.38 billion in 2025 and is projected to grow to USD 165.76 billion in 2026, with a CAGR of 9.01%, reaching USD 282.48 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 154.38 billion
Estimated Year [2026] USD 165.76 billion
Forecast Year [2032] USD 282.48 billion
CAGR (%) 9.01%

A concise orientation to genotyping advances, market dynamics, and strategic imperatives shaping how organizations harness genomic data for practical outcomes

Genotyping is now a foundational capability across life sciences, agriculture, and clinical practice, driven by converging technological maturity and expanding application demand. As precision biology moves from discovery to operational deployment, stakeholders require a clear framing of how core technologies, end-user requirements, and sample diversity interact to create both opportunity and complexity. This introduction situates current developments within that broader context, emphasizing pragmatic considerations such as assay reproducibility, sample provenance, workflow integration, and regulatory alignment.

Over the past decade, method-level innovations and process optimizations have lowered barriers to entry while simultaneously elevating expectations for data quality and interpretability. Consequently, organizations face trade-offs between throughput, per-sample cost, sensitivity, and bioinformatics burden. Readers should therefore anticipate that strategic decisions will hinge as much on systems design and vendor partnerships as on individual instrument capabilities. In addition, an evolving regulatory environment and shifting procurement practices are influencing timelines for clinical adoption and large-scale agricultural implementations. Taken together, these dynamics make a nuanced understanding of both technological characteristics and end-user workflows essential for effective planning and investment.

Emerging technological breakthroughs, regulatory catalysts, and business model transformations that are redefining genotyping practice and commercial pathways

The genotyping landscape is in the midst of several transformative shifts that are reshaping how research, diagnostics, and applied breeding programs operate. Technologically, the continued refinement of sequencing chemistries and the integration of digital PCR and advanced microarray modalities have improved sensitivity, reduced turnaround times, and enabled more flexible experimental designs. These advances are being amplified by improvements in bioinformatics pipelines, which reduce analytical bottlenecks and increase the reliability of variant calls across diverse sample types.

Concurrently, business models are evolving. Providers are moving from one-time instrument sales toward service-oriented offerings that bundle instruments, consumables, and cloud-enabled analytics. This transition is prompting new partnership structures between instrument manufacturers, reagent suppliers, and software firms. Regulatory maturation is also a critical inflection point; clearer guidance for diagnostic assays and harmonization efforts across jurisdictions are lowering entry barriers for clinically actionable genotyping tests, while creating more rigorous validation demands. Finally, ethical and data governance considerations are gaining prominence, requiring organizations to invest in consent frameworks and secure data architectures. In combination, these technological, commercial, and regulatory drivers are shifting competitive dynamics and creating pathways for accelerated adoption among well-prepared stakeholders.

Comprehensive assessment of how United States tariff measures introduced in 2025 influence supply chains, procurement strategies, and innovation in genotyping ecosystems

Tariff measures introduced by the United States in 2025 have produced a complex set of effects on genotyping ecosystems, influencing supply chains, component sourcing, and procurement strategies. Immediate operational impacts include elevated landed costs for imported instruments and reagents, prompting some buyers to re-evaluate supplier portfolios and to consider alternative sourcing strategies. In turn, procurement teams are placing greater emphasis on supplier resilience, local inventory buffers, and contractual protections to mitigate the risk of tariff-driven price volatility.

Beyond procurement, tariffs have incentivized manufacturers and distributors to reassess manufacturing footprints, with increasing consideration given to regionalization of production and nearshoring of critical reagent and instrument subassembly lines. This shift aims to reduce exposure to trade friction and to improve lead-time predictability. At the same time, some organizations are accelerating vertical integration to secure access to proprietary consumables and to preserve margins. Importantly, tariffs have also affected collaborative dynamics, encouraging closer partnerships between suppliers and large end users to underwrite inventory commitments or customized pricing arrangements. While these responses can enhance resilience, they also introduce strategic trade-offs around capital allocation and operational flexibility. Consequently, leadership teams must weigh short-term mitigation tactics against longer-term decisions about where to locate capacity and how to structure supplier relationships to support sustained innovation and reliable service delivery.

Granular segmentation insights illuminating technology, application, end-user and sample type dynamics that shape product adoption and innovation imperatives

A granular segmentation framework clarifies where value and technical differentiation are concentrated across the genotyping landscape. On the technology axis, distinctions among microarray, PCR, and sequencing platforms drive fundamentally different use cases and investment profiles. Microarray techniques, including comparative genomic hybridization and SNP arrays, remain relevant for targeted, cost-conscious genotyping and are commonly deployed for large-scale variant screening. PCR approaches, split between digital and real-time modalities, offer complementary strengths: digital PCR delivers ultra-sensitive quantitation for low-allele-fraction detection, while real-time PCR provides high-throughput, cost-effective workflows for routine assays. Sequencing encompasses both traditional Sanger approaches and next-generation sequencing, with next-generation methods further categorized into exome, targeted, and whole-genome applications that differ in breadth of genomic interrogation and downstream analytical complexity.

Turning to applications, agriculture, clinical diagnostics, and research exert distinct performance and regulatory demands. In agriculture, needs center on crop improvement and livestock breeding programs that require robust genotyping pipelines tolerant of diverse sample matrices and field-derived variability. Clinical diagnostics prioritize cancer profiling and pathogen detection, carrying stringent validation, traceability, and turnaround-time requirements. Research applications, such as gene expression analysis and genetic variation studies, often tolerate higher analytical complexity and iterative experimental designs. End-user segmentation differentiates academic and research institutes, diagnostic laboratories, and pharmaceutical and biotechnology companies, each with unique purchasing models, operational scales, and technical staff competencies. Lastly, sample-type segmentation-encompassing animal, human, microbial, and plant matrices-affects assay selection, extraction protocols, and quality-control thresholds. Synthesizing across these dimensions reveals that successful product and service strategies align technology capabilities to the nuanced demands of application domains, end-user workflows, and the idiosyncrasies of specific sample types.

Regional strategic perspectives across the Americas, Europe Middle East and Africa, and Asia-Pacific highlighting competitive strengths and capability gaps

Regional dynamics materially influence strategy and operations in the genotyping domain, with each geography presenting distinct strengths, constraints, and commercial channels. In the Americas, strong research infrastructure and a dense network of clinical and commercial laboratories drive rapid technology diffusion and a vibrant vendor ecosystem, while policy shifts and procurement practices can accelerate or constrain adoption cycles. Conversely, Europe, Middle East & Africa presents a heterogeneous environment in which robust regulatory frameworks in some jurisdictions coexist with capacity gaps elsewhere, creating both opportunities for centralized diagnostic services and challenges for equitable access across diverse markets. Stakeholders in this region often emphasize compliance, data protection, and cross-border collaboration as critical strategic considerations.

Meanwhile, the Asia-Pacific region exhibits rapid capacity expansion, driven by investments in sequencing infrastructure, government-backed genomics initiatives, and a growing base of local manufacturing and service providers. This regional momentum supports aggressive deployment in agricultural genomics and population-scale research, but it also raises competitive pressures and prompts incumbent international suppliers to adapt pricing and partnership models. Across all regions, differences in reimbursement environments, regulatory harmonization, and logistics performance shape procurement decisions and time-to-market timelines. Therefore, regional strategies should be calibrated to local regulatory regimes, talent availability, and supply-chain realities, while also factoring in opportunities for regional hubs and cross-border service models.

Competitive intelligence and corporate positioning analysis revealing strategic priorities, collaboration trends, and capability investments among leading genotyping firms

Corporate behavior in the genotyping space reflects a mix of technology-driven differentiation and strategic portfolio management. Leading companies are concentrating resources on high-value capabilities such as integrated sample-to-answer workflows, cloud-enabled analytics, and reagent portfolios that are co-validated with instruments. Partnerships between instrument vendors and software providers are increasingly common, enabling tighter integration of laboratory workflows and analytics while reducing time to actionable results. At the same time, several firms are pursuing vertical integration to control critical consumables and to protect margins against supply-chain disruption.

Competitive positioning also varies by focus area. Firms that emphasize assay robustness and regulatory-grade validation often target clinical diagnostic pathways, investing in quality systems and clinical partnerships. Companies that prioritize scalability and cost-efficiency direct efforts toward large-volume applications such as agricultural genotyping or population-scale research initiatives. Across the board, there is a discernible emphasis on service models that bundle instruments, reagents, and data interpretation to create predictable revenue streams and stronger customer lock-in. Strategic collaboration with contract research organizations, clinical networks, and agricultural extension services further extends reach and utility. Ultimately, successful companies balance short-term commercial execution with longer-term investment in platform extensibility and regulatory readiness.

High-impact strategic recommendations for industry leaders to accelerate technology adoption, secure supply chains, and capture value in genotyping landscapes

Industry leaders should pursue a set of prioritized actions to strengthen strategic positioning and operational resilience. First, align technology selection with end-user workflows by validating platform performance across the specific sample types and application contexts that matter to your customers. This alignment reduces downstream rework and accelerates adoption. Second, diversify supplier relationships and consider regional manufacturing or distribution partnerships to mitigate tariff exposure and logistic disruptions. Placing emphasis on contractual protections and inventory strategies can preserve service continuity while maintaining cost discipline.

Third, invest in integrated service models that combine instruments, consumables, and analytics into single offerings, thereby simplifying procurement and increasing perceived customer value. Fourth, accelerate investments in regulatory and quality capabilities to support clinical uptake, particularly for cancer profiling and pathogen detection assays that demand robust validation and traceability. Fifth, pursue partnerships with academic centers and agricultural research programs to pilot new applications and to co-develop validation studies that demonstrate real-world utility. Finally, embed data governance and ethical frameworks into product design and commercial agreements to address growing stakeholder expectations around consent, privacy, and data portability. Taken together, these recommendations will help organizations convert technological capabilities into sustainable competitive advantage while managing operational risk.

Rigorous research methodology detailing data sources, expert engagements, validation processes, and ethical safeguards applied throughout the genotyping study

The research underpinning this executive summary employed a multi-method approach designed to ensure rigor, transparency, and reproducibility. Primary data collection included structured interviews with practitioners across clinical laboratories, agricultural breeding operations, and academic research programs, augmented by consultations with procurement and regulatory specialists to capture operational and policy perspectives. Secondary research synthesized peer-reviewed literature, regulatory guidance, instrument and assay documentation, and publicly available corporate disclosures to triangulate findings and to contextualize technological trajectories.

Data validation techniques included cross-verification of interview insights with documented product specifications and third-party validation studies, as well as iterative review cycles with domain experts to resolve discrepancies. Ethical safeguards were applied throughout the research process, including anonymization of interview responses and adherence to data protection best practices. Limitations of the study were acknowledged, notably the evolving nature of regulatory landscapes and the variability of regional procurement practices, which can introduce heterogeneity in adoption patterns. Nonetheless, the methodological combination of expert input, document analysis, and validation cycles provides a robust foundation for the strategic conclusions and recommendations presented here.

Synthesis of implications for stakeholders, outlining strategic imperatives and pathways to resilience and growth within the evolving genotyping sector

In sum, genotyping is transitioning from a technology constrained to specialized laboratories into a distributed capability that supports diagnostics, agriculture, and research at scale. Technological advances in sequencing, microarray, and PCR modalities are expanding the range of feasible assays, while evolving commercial models and regulatory clarity are shaping adoption pathways. Tariff-induced dynamics in 2025 have underscored the importance of supply-chain resilience and have accelerated conversations around regional manufacturing and supplier diversification. Segmentation insights reveal that technology choice must be matched to application demands, end-user capabilities, and the specific challenges posed by different sample types.

For stakeholders, the imperative is clear: build adaptable strategies that align platform selection, procurement practices, and regulatory readiness with the practical realities of deployment. Organizations that invest in integrated offerings, robust validation frameworks, and partnerships that bridge technical expertise with domain-specific needs will be best positioned to convert capability into tangible outcomes. Looking ahead, sustained attention to data governance, interoperability, and workforce capability will be essential in translating genotyping innovations into reliable, ethical, and scalable solutions that meet both commercial and societal needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Genotyping Market, by Sample Type

  • 8.1. Animal
  • 8.2. Human
  • 8.3. Microbial
  • 8.4. Plant

9. Genotyping Market, by Technology

  • 9.1. Microarray
    • 9.1.1. Comparative Genomic Hybridization
    • 9.1.2. Snp Array
  • 9.2. Pcr
    • 9.2.1. Digital
    • 9.2.2. Real Time
  • 9.3. Sequencing
    • 9.3.1. Next Generation
      • 9.3.1.1. Exome
      • 9.3.1.2. Targeted
      • 9.3.1.3. Whole Genome
    • 9.3.2. Sanger

10. Genotyping Market, by Application

  • 10.1. Agriculture
    • 10.1.1. Crop Improvement
    • 10.1.2. Livestock Breeding
  • 10.2. Clinical Diagnostics
    • 10.2.1. Cancer Profiling
    • 10.2.2. Pathogen Detection
  • 10.3. Research
    • 10.3.1. Gene Expression Analysis
    • 10.3.2. Genetic Variation Studies

11. Genotyping Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Diagnostic Laboratories
  • 11.3. Pharmaceutical And Biotechnology Companies

12. Genotyping Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Genotyping Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Genotyping Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Genotyping Market

16. China Genotyping Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. BGI Genomics Co., Ltd.
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. Danaher Corporation
  • 17.9. Eurofins Scientific SE
  • 17.10. F. Hoffmann-La Roche Ltd
  • 17.11. Illumina, Inc.
  • 17.12. Merck KGaA
  • 17.13. Oxford Nanopore Technologies plc
  • 17.14. Pacific Biosciences of California, Inc.
  • 17.15. PerkinElmer, Inc.
  • 17.16. QIAGEN N.V.
  • 17.17. Revvity, Inc.
  • 17.18. Standard BioTools Inc.
  • 17.19. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENOTYPING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENOTYPING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENOTYPING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENOTYPING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENOTYPING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENOTYPING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENOTYPING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENOTYPING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GENOTYPING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GENOTYPING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENOTYPING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENOTYPING MARKET SIZE, BY ANIMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENOTYPING MARKET SIZE, BY ANIMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENOTYPING MARKET SIZE, BY ANIMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENOTYPING MARKET SIZE, BY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENOTYPING MARKET SIZE, BY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENOTYPING MARKET SIZE, BY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENOTYPING MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENOTYPING MARKET SIZE, BY MICROBIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENOTYPING MARKET SIZE, BY MICROBIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENOTYPING MARKET SIZE, BY PLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENOTYPING MARKET SIZE, BY PLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENOTYPING MARKET SIZE, BY PLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENOTYPING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENOTYPING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENOTYPING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENOTYPING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENOTYPING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENOTYPING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENOTYPING MARKET SIZE, BY SNP ARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENOTYPING MARKET SIZE, BY SNP ARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENOTYPING MARKET SIZE, BY SNP ARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENOTYPING MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENOTYPING MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENOTYPING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENOTYPING MARKET SIZE, BY DIGITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENOTYPING MARKET SIZE, BY DIGITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENOTYPING MARKET SIZE, BY DIGITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENOTYPING MARKET SIZE, BY REAL TIME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENOTYPING MARKET SIZE, BY REAL TIME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENOTYPING MARKET SIZE, BY REAL TIME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENOTYPING MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENOTYPING MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENOTYPING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENOTYPING MARKET SIZE, BY NEXT GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENOTYPING MARKET SIZE, BY NEXT GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENOTYPING MARKET SIZE, BY NEXT GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENOTYPING MARKET SIZE, BY EXOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENOTYPING MARKET SIZE, BY EXOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENOTYPING MARKET SIZE, BY EXOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENOTYPING MARKET SIZE, BY TARGETED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENOTYPING MARKET SIZE, BY TARGETED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENOTYPING MARKET SIZE, BY TARGETED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENOTYPING MARKET SIZE, BY WHOLE GENOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENOTYPING MARKET SIZE, BY WHOLE GENOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENOTYPING MARKET SIZE, BY WHOLE GENOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENOTYPING MARKET SIZE, BY SANGER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENOTYPING MARKET SIZE, BY SANGER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENOTYPING MARKET SIZE, BY SANGER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENOTYPING MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENOTYPING MARKET SIZE, BY AGRICULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENOTYPING MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENOTYPING MARKET SIZE, BY CROP IMPROVEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENOTYPING MARKET SIZE, BY CROP IMPROVEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENOTYPING MARKET SIZE, BY CROP IMPROVEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENOTYPING MARKET SIZE, BY LIVESTOCK BREEDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENOTYPING MARKET SIZE, BY LIVESTOCK BREEDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENOTYPING MARKET SIZE, BY LIVESTOCK BREEDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENOTYPING MARKET SIZE, BY CANCER PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENOTYPING MARKET SIZE, BY CANCER PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENOTYPING MARKET SIZE, BY CANCER PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENOTYPING MARKET SIZE, BY PATHOGEN DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENOTYPING MARKET SIZE, BY PATHOGEN DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENOTYPING MARKET SIZE, BY PATHOGEN DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENOTYPING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENOTYPING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENOTYPING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENOTYPING MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENOTYPING MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENOTYPING MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENOTYPING MARKET SIZE, BY GENETIC VARIATION STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENOTYPING MARKET SIZE, BY GENETIC VARIATION STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENOTYPING MARKET SIZE, BY GENETIC VARIATION STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENOTYPING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENOTYPING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENOTYPING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENOTYPING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENOTYPING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENOTYPING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENOTYPING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENOTYPING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENOTYPING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENOTYPING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS GENOTYPING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL GENOTYPING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GCC GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GCC GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. GCC GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. GCC GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 212. GCC GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 213. GCC GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 214. GCC GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. GCC GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 216. GCC GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 217. GCC GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 218. GCC GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. G7 GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. G7 GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. G7 GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. G7 GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 248. G7 GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 249. G7 GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 250. G7 GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. G7 GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 252. G7 GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 254. G7 GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. NATO GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. NATO GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. NATO GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. NATO GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 260. NATO GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 261. NATO GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 262. NATO GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. NATO GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 264. NATO GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 265. NATO GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 266. NATO GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES GENOTYPING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA GENOTYPING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)